ATE153699T1 - Therapeutische zusammensetzungen auf der basis von ribozymen - Google Patents

Therapeutische zusammensetzungen auf der basis von ribozymen

Info

Publication number
ATE153699T1
ATE153699T1 AT91917398T AT91917398T ATE153699T1 AT E153699 T1 ATE153699 T1 AT E153699T1 AT 91917398 T AT91917398 T AT 91917398T AT 91917398 T AT91917398 T AT 91917398T AT E153699 T1 ATE153699 T1 AT E153699T1
Authority
AT
Austria
Prior art keywords
sequence
ncca
complementary
region
rnase
Prior art date
Application number
AT91917398T
Other languages
English (en)
Inventor
Sidney Altman
Anthony C Forster
Cecilia L Guerrier-Takada
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of ATE153699T1 publication Critical patent/ATE153699T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/12Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/126Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT91917398T 1990-08-17 1991-08-15 Therapeutische zusammensetzungen auf der basis von ribozymen ATE153699T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/568,834 US5168053A (en) 1989-03-24 1990-08-17 Cleavage of targeted RNA by RNAase P

Publications (1)

Publication Number Publication Date
ATE153699T1 true ATE153699T1 (de) 1997-06-15

Family

ID=24272934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91917398T ATE153699T1 (de) 1990-08-17 1991-08-15 Therapeutische zusammensetzungen auf der basis von ribozymen

Country Status (9)

Country Link
US (1) US5168053A (de)
EP (1) EP0546092B1 (de)
JP (1) JPH06502761A (de)
AT (1) ATE153699T1 (de)
AU (2) AU659102B2 (de)
CA (1) CA2088917C (de)
DE (1) DE69126311T2 (de)
ES (1) ES2104722T3 (de)
WO (1) WO1992003566A1 (de)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
US5624824A (en) * 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5519164A (en) * 1990-02-01 1996-05-21 Hoechst Aktiengesellschaft Expression of a multigene RNA having self-splicing activity
AU669367B2 (en) * 1992-04-28 1996-06-06 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
JPH08500481A (ja) * 1992-05-11 1996-01-23 リボザイム・ファーマシューティカルズ・インコーポレーテッド ウイルスの複製を阻害するための方法および薬剤
US6017756A (en) * 1992-05-14 2000-01-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting hepatitis B virus replication
US5804683A (en) * 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US6258585B1 (en) 1992-05-14 2001-07-10 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting influenza virus replication
US5622854A (en) * 1992-05-14 1997-04-22 Ribozyme Pharmaceuticals Inc. Method and reagent for inhibiting T-cell leukemia virus replication
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5972699A (en) 1992-05-14 1999-10-26 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting herpes simplex virus replication
ATE312510T1 (de) * 1992-06-29 2005-12-15 Gene Shears Pty Ltd Nukleinsäuren und sie verwendende verfahren zur bekämpfung viraler pathogene
JPH07509133A (ja) * 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US5599704A (en) * 1992-08-26 1997-02-04 Ribozyme Pharmaceuticals, Inc. ErbB2/neu targeted ribozymes
US6544755B1 (en) * 1992-08-26 2003-04-08 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases by expression of the c-Myc gene
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5891684A (en) * 1992-10-15 1999-04-06 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
US5837542A (en) 1992-12-07 1998-11-17 Ribozyme Pharmaceuticals, Inc. Intercellular adhesion molecule-1 (ICAM-1) ribozymes
US5616488A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
US5612215A (en) * 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
US5811300A (en) * 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US5616490A (en) * 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. Ribozymes targeted to TNF-α RNA
US5658780A (en) * 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
US5698430A (en) * 1993-01-15 1997-12-16 Rubinstein; Alan I. Non-infective vaccines
US5639655A (en) * 1993-01-19 1997-06-17 Ribozyme Pharmaceuticals, Inc. PML-RARA targeted ribozymes
WO1994026877A1 (en) * 1993-05-17 1994-11-24 The Regents Of The University Of California Ribozyme gene therapy for hiv infection and aids
CA2176035A1 (en) 1993-11-08 1995-05-18 Nassim Usman Base-modified enzymatic nucleic acid
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5631148A (en) * 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
US6103890A (en) * 1994-05-18 2000-08-15 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids that cleave C-fos
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US5872241A (en) * 1995-01-25 1999-02-16 The Trustees Of Columbia University In The City Of New York Multiple component RNA catalysts and uses thereof
US5877162A (en) * 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
US6610478B1 (en) 1996-08-16 2003-08-26 Yale University Phenotypic conversion of cells mediated by external guide sequences
AU4071197A (en) * 1996-08-16 1998-03-06 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
EP0975651A4 (de) * 1997-02-26 2005-03-09 Gen Hospital Corp Transgene tiere und zellinien zur erkennung von zur behandlung oder vorbeugung der alzheimerschen krankheit wirksamen medikamente
US20030033621A1 (en) * 1997-02-26 2003-02-13 De La Monte Suzanne Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
US7226730B1 (en) 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
US6156953A (en) 1997-06-03 2000-12-05 University Of Chicago Plant artificial chromosome compositions and methods
US7154024B2 (en) * 1997-06-23 2006-12-26 Pioneer Hi-Bred, Inc. Male tissue-preferred regulatory sequences of Ms45 gene and method of using same
US6037523A (en) * 1997-06-23 2000-03-14 Pioneer Hi-Bred International Male tissue-preferred regulatory region and method of using same
WO1999027135A2 (en) * 1997-11-21 1999-06-03 Yale University Method for identifying and inhibiting functional nucleic acid molecules in cells
US6013447A (en) * 1997-11-21 2000-01-11 Innovir Laboratories, Inc. Random intracellular method for obtaining optimally active nucleic acid molecules
US6248525B1 (en) 1998-03-30 2001-06-19 Yale University Method for identifying essential or functional genes
EP1084227A4 (de) 1998-05-29 2002-06-12 Univ Jefferson Zusammensetzungen und methoden zur beeinflussung des wachsstums von hämatopoetischen stammzellpopulationen in säugetieren
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6489537B1 (en) 1998-08-07 2002-12-03 The Trustees Of The University Of Pennsylvania Phytochelatin synthases and uses therefor
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
WO2000064920A1 (en) 1999-04-27 2000-11-02 The Trustees Of The University Of Pennsylvania Compositions, methods, and kits relating to resistin
US6429357B1 (en) 1999-05-14 2002-08-06 Dekalb Genetics Corp. Rice actin 2 promoter and intron and methods for use thereof
EP1183333A4 (de) * 1999-05-19 2002-09-11 Smithkline Beecham Corp Verfahren zur verwendung der rnase p reaktion
DE60045931D1 (de) 1999-07-07 2011-06-16 Zymogenetics Inc Menschliches Rezeptor für Zytokine
US6852911B1 (en) 1999-08-31 2005-02-08 Fertiseed Ltd. Method of producing a male sterile plant by exogenic allelism
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
EP1950297A2 (de) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US20020165192A1 (en) * 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US20110052546A1 (en) * 2000-09-19 2011-03-03 University Of South Florida Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation
WO2002030465A2 (en) 2000-10-12 2002-04-18 University Of Rochester Compositions that inhibit proliferation of cancer cells
JP2004522432A (ja) * 2000-12-22 2004-07-29 シノヴィス・リミテッド Toll関連レセプター(trr)シグナル伝達の調節方法
EP2236156A3 (de) * 2001-01-09 2011-01-05 Baylor Research Institute Verfahren zur Behandlung und Diagnose von Psoriasis
EP1377680B1 (de) 2001-04-12 2011-10-05 Imperial Innovations Limited Diagnose und behandlung von brustkrebs mit scn5a
BR0209745A (pt) 2001-05-30 2004-08-10 Chromos Molecular Systems Inc Cromossomas artificiais de plantas, usos e dos mesmos e método para preparação de cromossomas artificiais de plantas
GB0116249D0 (en) * 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
AU2002322515A1 (en) * 2001-07-17 2003-03-03 Keith Choate Compositions, methods, and kits related to treating and diagnosing hypertension
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
DE60237696D1 (de) * 2001-08-01 2010-10-28 Univ Utah Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
EP2311852A1 (de) 2002-02-06 2011-04-20 Stasys Technologies, Inc. Anti-Infarkt-Moleküle
US20040005546A1 (en) * 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
WO2004013160A2 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003285887B2 (en) 2002-10-11 2008-09-11 Novocell, Inc. Implantation of encapsulated biological materials for treating diseases
US9233120B2 (en) 2002-11-15 2016-01-12 Jyant Technologies Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration
US8512701B2 (en) 2002-11-15 2013-08-20 Morehouse School Of Medicine Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration
US8658377B2 (en) 2002-11-15 2014-02-25 Morehouse School Of Medicine Detecting cancer with anti-CCL25 and anti-CCR9 antibodies
EP1613269B1 (de) 2003-04-04 2015-02-25 Incyte Corporation Zusammensetzungen, verfahren und kits in zusammenhang mit her-2 spaltung
EP2295586A3 (de) 2003-06-27 2011-06-29 Chromatin, Inc. Pflanzenzentromerzusammensetzungen
EP2357240A1 (de) 2003-06-27 2011-08-17 Chromatin, Inc. Pflanzenzentromerzusammensetzungen
WO2005012548A2 (en) * 2003-08-01 2005-02-10 Dynal Biotech Inc. Self-hybridizing multiple target nucleic acid probes and methods of use
GB0322689D0 (en) * 2003-09-27 2003-10-29 Medical Res Council Methods
EP2083089A1 (de) 2003-10-23 2009-07-29 Illumigen Biosciences, Inc. Nachweis von Mutationen in einem mit der Resistenz gegenüber einer Virusinfektion assoziierten Gen, oas1
US7807646B1 (en) * 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
EP1694666A4 (de) * 2003-12-19 2008-09-17 Philadelphia Health & Educatio Neue gespleiste 5-ht1a-rezeptoren und damit in zusammenhang stehende verfahren, kits und anwendungen
CA2559853A1 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
CA2574572A1 (en) * 2004-07-19 2006-10-26 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
CA2593956A1 (en) * 2004-12-22 2006-06-29 Lipopeptide Ab Agents inhibiting the cathelin-like protein cap18/ll-37
SI2567976T1 (sl) 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
US7476733B2 (en) 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US20070048293A1 (en) * 2005-05-31 2007-03-01 The Trustees Of The University Of Pennsylvania Manipulation of PTEN in T cells as a strategy to modulate immune responses
WO2006135862A2 (en) * 2005-06-10 2006-12-21 Children's Hospital And Research Center At Oakland Immunomodulation by altering sphingosine 1-phosphate lyase (spl) activity
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
US8029989B2 (en) * 2005-08-26 2011-10-04 The Trustees Of The University Of Pennsylvania Method using snail transcriptional repressor
US8222028B2 (en) 2005-09-08 2012-07-17 Chromatin, Inc. Plants modified with mini-chromosomes
EP1934244A2 (de) * 2005-10-06 2008-06-25 Emthrax LLC Verfahren und zusammensetzungen in verbindung mit milzbrandsporen-glycoproteinen als impfstoffe
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
CA2625891A1 (en) 2005-10-14 2007-04-26 Carlton D. Donald Inhibition of pax2 by defb1 induction as a therapy for cancer
US8470965B2 (en) 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CA2644952A1 (en) 2006-03-01 2007-09-13 The University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
GB0607354D0 (en) * 2006-04-12 2006-05-24 Bioinvent Int Ab Agent, Composition And Method
EP2051585A4 (de) * 2006-04-28 2010-06-02 Univ South Florida Materialien und verfahren zur unterdrückung von entzündungen durch hemmung des vorhof-rezeptors für natriuretische peptide
EP2560001B1 (de) 2006-09-21 2016-04-13 University of Rochester Zusammensetzungen und Verfahren für eine Proteinverlagerungstherapie für myotone Dystrophie
EP1914303A1 (de) 2006-10-09 2008-04-23 Qiagen GmbH Thermus eggertssonii DNA Polymerasen
EP2104516B1 (de) 2006-11-01 2015-01-07 University of Rochester Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
US7994130B2 (en) 2006-12-11 2011-08-09 University Of Utah Research Foundation Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability
US9896511B2 (en) 2007-01-10 2018-02-20 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
WO2008147526A1 (en) 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
WO2009026496A1 (en) * 2007-08-22 2009-02-26 University Of Southern California Grp78 and tumor angiogenesis
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
JP2011505144A (ja) * 2007-11-30 2011-02-24 ベイラー カレッジ オブ メディシン 樹状細胞ワクチン組成物およびその使用
US8501912B2 (en) 2007-12-03 2013-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Filipil compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
DE102008014041A1 (de) * 2008-03-13 2009-09-17 Leibniz-Institut für Pflanzengenetik Und Kulturpflanzenforschung (IPK) Verfahren zur Erzeugung einer Breitband-Resistenz gegenüber Pilzen in transgenen Pflanzen
EP2853897A1 (de) 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensorische Rezeptoren für chronische Müdigkeit und Schmerzen und Verwendungen davon
EP2370080A1 (de) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 als zieltherapeutikum bei herzkrankheiten
US20110318738A1 (en) 2008-12-23 2011-12-29 University Of Utah Research Foundation Identification and regulation of a novel dna demethylase system
CN102341106A (zh) 2009-02-13 2012-02-01 印第安那大学科技研究公司 用于抑制mmp2和mmp9的化合物和方法
GB0904904D0 (en) 2009-03-23 2009-05-06 Univ Leiden Medical Ct Angiogenesis methods, medicaments and agents
US20120077753A1 (en) 2009-06-25 2012-03-29 Laxman Gangwani Jnk inhibitors for use in treating spinal muscular atrophy
GB0912624D0 (en) 2009-07-21 2009-08-26 Imp Innovations Ltd Methods
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
WO2011062962A2 (en) 2009-11-17 2011-05-26 The Trustees Of The University Of Pennsylvania Smndelta7 degron: novel compositions and methods of use
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
WO2012058532A2 (en) 2010-10-28 2012-05-03 Yale University Methods and compositions for assessing and treating cancer
DK2643470T3 (en) 2010-11-24 2016-05-17 Univ Yale Preparations and methods for treating ischemic injury with D-DT
CN106177930A (zh) 2010-12-14 2016-12-07 吉安特科技股份有限公司 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途
US20140030218A1 (en) 2011-01-05 2014-01-30 Imperial Innovations Limited Treatment And Screening
EP2476441A1 (de) 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Verfahren und Reagenzien zur effizienten und gezielten Abgabe von therapeutischen Molekülen an CXCR4-Zellen
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
MX2013013329A (es) 2011-05-20 2014-04-16 Us Government Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos.
GB201110546D0 (en) 2011-06-22 2011-08-03 Imp Innovations Ltd Compositions
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
EP2763540A4 (de) 2011-09-09 2015-04-22 Univ Yale Zusammensetzungen und verfahren zur beurteilung und behandlung von entzündlichen krankheiten und erkrankungen
WO2013044116A1 (en) 2011-09-21 2013-03-28 Yale University Antimicrobial compositions and methods of use thereof
WO2013050593A1 (en) 2011-10-07 2013-04-11 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013050611A1 (en) 2011-10-07 2013-04-11 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013053686A1 (en) 2011-10-10 2013-04-18 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
WO2013053711A1 (en) 2011-10-10 2013-04-18 Basf Plant Science Company Gmbh Method of producing plants having increased resistance to pathogens
US20140170159A9 (en) 2012-03-08 2014-06-19 Ge Wei Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
ES2785274T3 (es) 2012-07-05 2020-10-06 Univ Pennsylvania La RNPsn U1 regula la expresión génica y modula la oncogenicidad
ES2905360T3 (es) 2012-07-16 2022-04-08 Univ Yale Composiciones y métodos para detectar, tratar y prevenir enfermedades y trastornos
US9937205B2 (en) 2012-09-04 2018-04-10 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
KR102092435B1 (ko) 2013-03-08 2020-03-24 예일 유니버시티 피부색소침착 감소용 조성물 및 방법
EA201600252A1 (ru) 2013-09-12 2017-05-31 Галозим, Инк. Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
WO2015175884A2 (en) 2014-05-16 2015-11-19 Yale University Compositions and methods for treating and preventing pancreatitis, renal injury and cancer
EP3160493A4 (de) 2014-06-26 2018-04-11 Yale University Zusammensetzungen und verfahren zur renalaseregulierung bei der behandlung von erkrankungen und störungen
EP3164194B1 (de) 2014-07-03 2021-11-24 Yale University Dickkopf2 (dkk2)-hemmung zur unterdrückung der tumorbildung
BR112017001860A2 (pt) 2014-07-31 2018-02-27 Uab Research Foundation peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
WO2016069607A1 (en) 2014-10-27 2016-05-06 University Of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
WO2016081796A1 (en) 2014-11-21 2016-05-26 Yale University Compositions and methods for modulating salm5 and hvem
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
US10723794B2 (en) 2015-03-18 2020-07-28 University Of South Carolina Anti-CcL8 antibodies and uses thereof
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US20190119364A1 (en) 2016-04-29 2019-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
KR20190037273A (ko) 2016-08-03 2019-04-05 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 Tlr9 표적 치료제
EP3625248A4 (de) 2017-05-18 2021-01-20 The Rockefeller University Zusammensetzungen und verfahren zur diagnose und behandlung von erkrankungen und leiden im zusammenhang mit kcnj5-mutationen
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
CN113409890B (zh) * 2021-05-21 2022-04-12 银丰基因科技有限公司 一种基于二代测序数据的hla分型方法
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
ATE115999T1 (de) * 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.

Also Published As

Publication number Publication date
EP0546092B1 (de) 1997-05-28
WO1992003566A1 (en) 1992-03-05
DE69126311T2 (de) 1998-01-08
EP0546092A1 (de) 1993-06-16
AU675613B2 (en) 1997-02-06
AU8627391A (en) 1992-03-17
AU659102B2 (en) 1995-05-11
AU1647095A (en) 1995-06-22
JPH06502761A (ja) 1994-03-31
ES2104722T3 (es) 1997-10-16
US5168053A (en) 1992-12-01
CA2088917C (en) 2002-11-12
EP0546092A4 (en) 1993-10-13
CA2088917A1 (en) 1992-02-18
DE69126311D1 (de) 1997-07-03

Similar Documents

Publication Publication Date Title
ATE153699T1 (de) Therapeutische zusammensetzungen auf der basis von ribozymen
KR900700603A (ko) 리보자임
KR930701466A (ko) 안티센스 올리고뉴클레오티드에 의한 a형 인플루엔자 바이러스, 안 아아보 스트레인(ann arbor strain)h2n2의 억제
US20180179526A1 (en) Method and Medicament For Inhibiting The Expression of A Given Gene
FI946201A0 (fi) Itsestabiloidut oligonukleotidit terapeuttisina aineina
RU95104940A (ru) Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения
ATE460481T1 (de) Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
KR960704033A (ko) 인간 면역결핍 바이러스에 대한 활성을 갖는 올리고뉴클레오티드(Oligonucleotides with Activity against Humand Immunodeficiency Virus)
DE69432315D1 (de) ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT
FI20030248A (fi) Proteiinikinaasi C:tä koodaavaan mRNA:han hybridisoituvia oligonukleotideja
DE69620906T2 (de) Antisense-oligonukleotidmodulation der raf-genexpression
FI951600A (fi) Terapeuttinen HIV:n vastainen oligonukleotidi ja lääkeaine
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
DE69634698D1 (de) Gewebespezifische und ziel-rna-spezifische ribozyme
KR960704034A (ko) 단백질 생산, 세포 증식 및(또는) 전염병 병원균의 증식에 대한 올리고뉴클레오티드 저해의 향상법(Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and/or Multiplication of Infectious Disease Pathogens)
ATE163973T1 (de) Antisense oligonukleotidhemmung von papillomavirus
JP2002521070A5 (de)
SE9503117D0 (sv) Novel use of padlock probes
ES2112062T3 (es) Oligonucleotidos con actividad anti-citomegalovirus.
ATE337404T1 (de) Zur verleihung viraler resistenz an pflanzen geeignetes polyribozym und dieses polyribozym produzierende resistente pflanzen
RU2008130901A (ru) iPHK-ОПОСРЕДОВАНННОЕ ИНГИБИРОВАНИЕ IGFR ДЛЯ ЛЕЧЕНИЯ ГЛАЗНОГО АНГИОГЕНЕЗА
US7148044B1 (en) Nucleic acid enzyme for RNA cleavage
ATE318617T1 (de) Synthetische oligonukleotide als erythroid differenzierungserreger
DE4427219A1 (de) Nukleinsäure zur Initiation der Aktivität von RNase H bzw. reverser Transkriptase
TH48691A (th) ผลิตภัณฑ์จาก rna สายคู่อย่างน้อย 1ชนิด รวมกับสารต่อต้านไวรัสอย่างน้อย1 ชนิด ที่มีสรรพคุณในการรักษาโรคที่เกิดจากไวรัส โดยเฉพาะโรคตับอักเสบที่เกิดจากเชื้อไวรัส

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties